Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

COMPARISON OF FINAL HEIGHTS OF GH TREATED VERSUS UNTREATED CHILDREN WITH IDIOPATHIC GROWTH FAILURE. † 494

We measured adult heights of 95 healthy GH sufficient children (peak GH> 10 ng/ml, polyclonal RIA) whose heights at presentation were more than 2 standard deviations (SD) below the mean for chronological age (CA), normal weight to height ratios, normal body proportions, and pathologic growth velocity for CA. Group 1 (N=32, 4 females) received standardized doses (0.3 mg/kg/week) of growth hormone (mean duration = 40 months, range 16 to 66 months), while group 2 (N=63, 17 females) received no treatment. Baseline data and height outcomes as follows (mean): Conclusion: Final height SDS in the GH treated group was significantly greater than in the untreated group, p<.001. Target height was met or exceeded by 44% of the GH treated group but only 13% of the untreated group. Predicted height was met or exceeded by 67% of the GH treated group in contrast to 43% for the untreated group. We conclude that GH treatment provided better height outcomes for the majority of children with idiopathic growth failure. Table

Table 1

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Buchlis, J., Irizarry, L., Crotzer, B. et al. COMPARISON OF FINAL HEIGHTS OF GH TREATED VERSUS UNTREATED CHILDREN WITH IDIOPATHIC GROWTH FAILURE. † 494. Pediatr Res 39, 85 (1996). https://doi.org/10.1203/00006450-199604001-00514

Download citation

Search

Quick links